TTrialPathMatch Me to Trials
← Back to trials
RecruitingAsthma

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.

Sponsor: AstraZeneca

You may qualify if…

  • ✓ 1. Documented physician-diagnosed asthma for at least 12 months prior to Visit 1
  • ✓ 2. Receiving 1 of the scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1
  • ✓ 3. Pre-bronchodilator FEV1 of ≥ 40% to \< 90% predicted normal value for adults.
  • ✓ 4. Documented reversibility to albuterol
  • ✓ 5. A documented history of at least one severe asthma exacerbation within 12 months before Visit 1
  • ✓ 6. ACQ-7 score ≥ 1.5 assessed at Visit 1
  • ✓ 7. ACQ-5 score ≥ 1.5 assessed at Visit 2
  • ✓ 8. Receiving inhaled SABA as needed prior to Visit 1 for at least 3 months

You may not qualify if…

  • ✕ 1. Chronic obstructive pulmonary disease or other significant lung disease
  • ✕ 2. Oral/SCS use (any dose) within 6 weeks before Visit 1
  • ✕ 3. Chronic use of OCS ≥ 3 weeks use in 3 months prior to Visit 1
  • ✕ 4. Having received any marketed or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication
  • ✕ 5. Current smokers, former smokers with \> 10 pack-years history, or former smokers who stopped smoking \< 6 months before Visit 1
  • ✕ 6. Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within last 5 years of Visit 1
  • ✕ 7. Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks of Visit 1
  • ✕ 8. Upper respiratory infection involving antibiotic treatment not resolved within 7 days before Visit 1

Source: ClinicalTrials.gov · NCT06471257 · last updated 2026-09-21

A Study to Investigate Efficacy and Safety of PT027 Compared With PT00 · TrialPath